Transebacillus Biotech

Transebacillus Biotech is a clinical-stage biotechnology company based in China that specializes in the development of novel microbial therapies for oncology. The company's lead program involves the use of a specific bacterial strain from the Transebacillus genus, which is being investigated for its ability to treat malignant pleural and abdominal effusions through localized administration. By leveraging the unique properties of these bacteria to modulate the tumor microenvironment and stimulate an anti-tumor immune response, Transebacillus Biotech aims to provide new therapeutic options for patients with advanced solid tumors. The company is currently conducting first-in-human Phase I/II clinical trials to evaluate the safety, tolerability, and preliminary efficacy of its lead candidate.